ALK and non-small cell lung carcinoma: For patients with PD-L1 TC ≥50% stage II-IIIA NSCLC without EGFR mutations or ALK rearrangements, the 5-year OS rates in the atezolizumab group and control group were 84.8% and 67.5%, respectively (HR=0.42, 95% CI: 0.23-0.78) (Figure 3A).